Last reviewed · How we verify
XmAb7195
At a glance
| Generic name | XmAb7195 |
|---|---|
| Sponsor | Xencor, Inc. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Safety, Tolerability, and Bioavailability of Subcutaneously Administered XmAb®7195 (PHASE1)
- Safety and Tolerability of XmAb®7195 in Adult Healthy Volunteers and Adult Subjects With a History of Allergic Rhinitis and/or Allergic Conjunctivitis and/or Atopic Dermatitis (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- XmAb7195 CI brief — competitive landscape report
- XmAb7195 updates RSS · CI watch RSS
- Xencor, Inc. portfolio CI